Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Progyny ( (PGNY) ) just unveiled an update.
Progyny, Inc. reported strong financial results for the third quarter of 2025, with a 9.3% increase in revenue to $313.3 million compared to the same period in 2024. The company achieved significant growth in its client base, adding over 80 new clients and nearly 900,000 new lives, while maintaining a near 100% client retention rate. The company’s operating cash flow reached a record $156 million for the first nine months of 2025, and it announced a $200 million share repurchase program, reflecting its robust financial position and commitment to returning value to shareholders.
The most recent analyst rating on (PGNY) stock is a Hold with a $23.00 price target. To see the full list of analyst forecasts on Progyny stock, see the PGNY Stock Forecast page.
Spark’s Take on PGNY Stock
According to Spark, TipRanks’ AI Analyst, PGNY is a Outperform.
Progyny’s overall stock score reflects strong financial performance and a positive outlook from recent earnings, despite technical indicators suggesting bearish momentum. The company’s strategic initiatives and increased guidance are significant positives, but high valuation and cash flow management concerns temper the score.
To see Spark’s full report on PGNY stock, click here.
More about Progyny
Progyny, Inc. is a global leader in women’s health and family building solutions, offering fertility and pharmacy benefit services. The company focuses on providing comprehensive care management services, including programs for pregnancy-postpartum, menopause, and leave and benefit navigation.
Average Trading Volume: 1,318,932
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.6B
See more data about PGNY stock on TipRanks’ Stock Analysis page.